Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System
Current Oncology · 2025
DOI: 10.3390/curroncol32020080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Felix E G Beaudry und 20 weiteren Autor:innen. Beteiligte Einrichtung: Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Legresley Family Foundation, Princess Margaret Cancer Foundation, The Terry Fox Research Institute (TFRI) Marathon of Hope Cancer Centres Network.
Abstract (Originalsprache)
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a public healthcare system is unknown. Here, BTC patients prospectively received WGTS to inform clinical care at a large Canadian academic cancer center. We characterized the proportion of targetable alterations, the treatment recommendations generated by a molecular tumor board, targeted therapies received, patient outcomes, and the financing of these treatments. A total of 55 patients with BTC prospectively underwent WGTS to inform clinical care. Of those 55, 28 (51%, 95% CI 38–64%) harbored targetable alterations. Molecular tumor boards recommended consideration of targeted therapies for 43 (78% CI: 66–87%) of 55 cases. Among the 15 patients who progressed to second-line therapy and harbored targetable alterations, 8 received nine targeted therapies. No targeted therapies were funded through the public system, and most therapies were funded through compassionate access programs from companies. These results highlight the challenges and potential for inequities when implementing precision oncology in a publicly funded healthcare system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ontario Institute for Cancer Research, Toronto, ON M5G 1M1, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
- Toronto General Hospital, Toronto, ON M5G 2C4, Canada.
- Department of Surgery, University of Toronto, Toronto, ON M5G 2C4, Canada.
- Eliot Phillipson Clinician-Scientist Training Program, University of Toronto, Toronto, ON M5S 3H2, Canada.
- Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada.
ORCID-Profile: Zhihao Li, Ayelet Borgida, Xin Wang, Anna Dodd, Julie Wilson
Förderung
- Legresley Family Foundation
- Princess Margaret Cancer Foundation
- The Terry Fox Research Institute (TFRI) Marathon of Hope Cancer Centres Network
Zitieren
APA
Beaudry, F. E. G., Li, Z., Borgida, A., Zorigtbaatar, A., Wang, X., Hildebrand, M., Hamza, O., Jang, G. H., Bucur, R., Dodd, A., Wilson, J., Auer, R. C., Saibil, S., Tsang, E. S., Vogel, A., O'Kane, G. M., Gallinger, S., Knox, J. J., Notta, F., …, & Grant, R. C. (2025). Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System. Current Oncology. https://doi.org/10.3390/curroncol32020080
Vancouver
Beaudry FEG, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M, et al. Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System. Current Oncology. 2025. doi:10.3390/curroncol32020080
BibTeX
@article{Beaudry2025,
author = {Beaudry, Felix E G and Li, Zhihao and Borgida, Ayelet and Zorigtbaatar, Anudari and Wang, Xin and Hildebrand, Maggie and Hamza, Oumaima and Jang, Gun Ho and Bucur, Roxana and Dodd, Anna and Wilson, Julie and Auer, Rebecca C and Saibil, Samuel and Tsang, Erica S and Vogel, Arndt and O'Kane, Grainne M and Gallinger, Steven and Knox, Jennifer J and Notta, Faiyaz and Sapisochin, Gonzalo and Grant, Robert C},
title = {Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32020080}
}
EUVIMED